Delivery Order SPE2DB20D3101-SPE2DB25FRWN8
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 19, 2025, for 100-unit vials of Xeomin with a ceiling value of $3,352.44. This firm fixed-price delivery order is scheduled for completion by October 10, 2025, and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. The award is not designated as a set-aside contract, indicating it was competitively awarded through open competition. This delivery order is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for the supply of Xeomin 100 Unit Vials with a ceiling value of $35,535.50 under a firm fixed-price contract. This non-set-aside award is scheduled for completion by October 8, 2025, with performance taking place at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. The delivery order represents a competitively awarded procurement action sourced through the company's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 18, 2025, for the supply of Xeomin 100 Unit Vials, with a ceiling value of $5,989.62 and an ultimate completion date of October 9, 2025. This is a firm fixed price delivery order with no set-aside designation, competitively awarded under an open procurement process. The place of performance is AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania, where the company serves as a...
- The Defense Logistics Agency awarded a $1,396.85 delivery order to AmerisourceBergen Drug Corp on July 17, 2025, for the supply of Xeomin 100 unit vials, with an ultimate completion date of August 7, 2025. This is a firm fixed price contract with no set-aside designation, indicating it was competitively awarded. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is a child contract issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Xeomin 100 unit vials valued at $6,704.88 with a firm fixed price structure. The order is scheduled for completion by August 19, 2025, and will be fulfilled from the vendor's Conshohocken, Pennsylvania location. This delivery order represents a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a...
- The Defense Logistics Agency awarded a $5,028.66 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of Xeomin 100 Unit Vials, with completion targeted for October 7, 2025. This competitively awarded contract contains no set-aside designation and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 and extending through December 2026. The...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 15, 2025, for the supply of Xeomin 200 unit vials valued at $46,934.16, with completion scheduled for October 6, 2025. This firm fixed price delivery order was competitively awarded with no set-aside designation and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 11, 2025, for the supply of Xeomin 200 Unit Vials with a ceiling value of $2,793.70 and an ultimate completion date of October 2, 2025. This firm fixed price, competitively awarded delivery order carries no set-aside designation and represents a child contract under AmerisourceBergen's larger pharmaceutical supply vehicle. The place of performance is listed as Conshohocken, Pennsylvania, which...
- The Defense Logistics Agency awarded a delivery order valued at $5,587.40 to AmerisourceBergen Drug Corp for the supply of Xeomin 200 unit vials, with performance to be completed by August 25, 2025. This competitively awarded, firm fixed-price delivery order was issued on August 4, 2025, with performance taking place at the vendor's corporate office location in Conshohocken, Pennsylvania. The award carries no set-aside designation, indicating it was competed among all eligible contractors....
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Xeomin 50 unit vials valued at $10,941.84. This competitively awarded, non-set-aside contract is structured as a firm fixed price delivery order with a completion date of September 10, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. The delivery order falls under the...
- SPE2DB20D3101Indefinite Delivery Contract
- SPE2DB20D3101-SPE2DB25FRWN8Delivery Order
The Defense Logistics Agency awarded a $3,352.44 delivery order to AmerisourceBergen Drug Corp on September 25, 2025, for the supply of Xeomin 100 unit vials, with performance completion scheduled for October 17, 2025. This is a firm fixed-price delivery order with no set-aside designation, indicating the contract was competitively awarded. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated as SPE2DX and valued at $999,999,999.00 through December 2026, which serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs. AmerisourceBergen Drug Corp, as a major pharmaceutical distributor and critical federal medical procurement vendor, supplies a comprehensive range of pharmaceutical products and medical supplies to support Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The Xeomin order falls within the company's extensive portfolio of neurological treatments and specialty medications delivered through the DLA Medical Supply Chain. The SPE2DX contract represents a strategic approach by DLA Troop Support to leverage prime vendor relationships for pharmaceutical support, with the agency planning to establish next-generation Pharmaceutical Prime Vendor Global Program contracts potentially involving multiple regional awards across several contractors.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.4k | 9/25/25 |